Selling Buzz: Harmony Biosciences Holdings Inc [HRMY] CHIEF FINANCIAL OFFICER Kapadia Sandip sells 20,000 shares of the company

Roman Campbell

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Harmony Biosciences Holdings Inc shares valued at $790,896 were sold by Kapadia Sandip on Dec 05 ’25. At $39.54 per share, Kapadia Sandip sold 20,000 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.

Also, SANDIP KAPADIA purchased 20,000 shares, netting a total of over 765,000 in proceeds.

Before that, Kapadia Sandip had sold 3,427 shares from its account. In a trade valued at $119,945, the CHIEF FINANCIAL OFFICER traded Harmony Biosciences Holdings Inc shares for $35.00 each. Upon closing the transaction, the insider’s holdings decreased to 3,427 shares, worth approximately $0.0.

As published in their initiating research note from Truist on July 21, 2025, Harmony Biosciences Holdings Inc [HRMY] has been a Buy and the price target has been revised to $48. Earlier on February 11, 2025, Deutsche Bank initiated its rating. Their recommendation was “a Buy” for HRMY stock.

Analyzing HRMY Stock Performance

On last trading session, Harmony Biosciences Holdings Inc [NASDAQ: HRMY] rose 0.81% to $39.59. The stock’s lowest price that day was $39.17, but it reached a high of $40.09 in the same session. During the last five days, there has been a surge of approximately 3.50%. Over the course of the year, Harmony Biosciences Holdings Inc shares have jumped approximately 18.25%. Shares of the company reached a 52-week high of $40.93 on 01/21/25 and a 52-week low of $25.52 on 10/20/25.

Support And Resistance Levels for Harmony Biosciences Holdings Inc (HRMY)

According to the 24-hour chart, there is a support level at 39.14, which, if violated, would cause prices to drop to 38.69. In the upper region, resistance lies at 40.07. The next price resistance is at 40.55. RSI (Relative Strength Index) is 77.83 on the 14-day chart, showing overbought technical sentiment.

Is Harmony Biosciences Holdings Inc subject to short interest?

Stocks of Harmony Biosciences Holdings Inc saw a sharp rise in short interest on 2025-11-28 jumping by 0.33 million shares to 4.41 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 4.08 million shares. A jump of 7.48% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.9 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.9.

Which companies own the most shares of Harmony Biosciences Holdings Inc (HRMY)?

In terms of Harmony Biosciences Holdings Inc share price expectations, FactSet research, analysts set an average price target of 46 in the next 12 months, up nearly 17.14% from the previous closing price of $39.27. Analysts anticipate Harmony Biosciences Holdings Inc stock to reach 62 by 2025, with the lowest price target being 33. In spite of this, 6 analysts ranked Harmony Biosciences Holdings Inc stock as Buy at the end of 2025. On December 17, 2024, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $75.

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.